Please login to the form below

Not currently logged in
Email:
Password:

Opdivo

This page shows the latest Opdivo news and features for those working in and with pharma, biotech and healthcare.

EU approval for Opdivo combo in renal cell cancer

EU approval for Opdivo combo in renal cell cancer

Median OS in patients treated with Opdivo plus low-dose Yervoy was not yet reached, compared to 25.9 months for patients treated with sunitinib. ... The European approval is important for BMS, as it seeks to maintain Opdivo’s blockbuster growth,

Latest news

More from news
Approximately 124 fully matching, plus 171 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    Indeed, BMS will pitch Opdivo at half the US list price, determining the true value of market access. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    their blockbuster checkpoint inhibitors Keytruda and Opdivo. ... CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    It’s not all been plain sailing, with BMS’ Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... Opdivo after standard treatment of early-stage

  • The good, the bad and the ugly The good, the bad and the ugly

    Though its main competitor, BMS’ Opdivo, was first to the NSCLC market, Merck’s frontline trial for Keytruda succeeded whereas Opdivo’s failed.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda. ... BMS looks unlikely to take the lead again, but Boerner can ensure Opdivo remains

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results. ... Bristol-Myers Squibb's  (BMS, $BMY) immunotherapy wonder drug  Opdivo (nivolumab) was poised for lasting success.

  • Video: Immuno-oncology therapies

    high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.

  • Video: Immuno-oncology therapies

    However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.

  • ASCO 2015: What you missed in Chicago

    In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... challenge Opdivo will depend on how the European markets provide access to it, as well as how issues of cost versus

  • Blue Latitude Health

    A stumble, but not a fall – what’s next for Opdivo?. ... Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics